Table of Contents
Chapter 1. Executive Summary
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.3 Assumptions
2.4 Limitations
Chapter 3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
Chapter 4. Market Dynamics
4.1 Overview
4.2 Drivers
4.3 Restraints
4.4 Opportunities
4.5 Pipeline Analysis
4.5 Macroeconomic Indicators
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Opportunities
Chapter 6. Global Hepatitis Test Solution Diagnosis Market, by Disease Type
6.1 Overview
6.2 Hepatitis A
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
6.3 Hepatitis B
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
6.3 Hepatitis C
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
6.5 Others
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
Chapter 7. Global Hepatitis Test Solution Diagnosis Market, by Type of Technology
7.1 Overview
7.2 Nucleic Acid Testing (NAT)
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.3 Enzyme-Linked Immunosorbent Assay (ELISA)
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.4 Rapid Diagnostic Tests (RDT)
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.5 Chemiluminescence immunoassay (CLIA)
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.6 Genotyping
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.7 Other
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
Chapter 8. Global Hepatitis Test Solution Diagnosis Market, by End User
8.1 Overview
8.2 Hospitals
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.3 Diagnostic Laboratories
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.4 Blood Banks
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.5 Research institutes
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.5 Others
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
Chapter 9. Global Hepatitis Test Solution Diagnosis Market, by Region
9.1 Overview
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 Latin America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa
Chapter 10. Company Landscape
10.1 Overview
10.2 Market Share Analysis
10.3 Key Development & Strategies
Chapter 11 Company Profiles
11.1 Abbott
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financial Overview
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.1.6 Key Strategies
11.2 Biomérieux Sa
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.2.6 Key Strategies
11.3 Bio-Rad Laboratories, Inc.
11.4 Danaher
11.4.1 Company Overview
11.4.2 Product Overview
11.4.3 Financial Overview
11.4.4 Key Developments
11.4.5 SWOT Analysis
11.4.6 Key Strategies
11.5 DiaSorin S.p.A.
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial Overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.5.6 Key Strategies
11.6 Miraca Holdings Inc. (Fujirebio, Inc.)
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.6.6 Key Strategies
11.7 Grifols
11.7.1 Company Overview
11.7.2 Product Overview
11.7.3 Financial Overview
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.7.6 Key Strategies
11.8 Onsite Lab Holding AG (MedMira, Inc.)
11.8.1 Company Overview
11.8.2 Product Overview
11.8.3 Financial Overview
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.8.6 Key Strategies
11.9 Qiagen
11.9.1 Company Overview
11.9.2 Product Overview
11.9.3 Financial Overview
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.9.6 Key Strategies
11.10 Roche Holding AG (Roche Diagnostics)
11.10.1 Company Overview
11.10.2 Product Overview
11.10.3 Financial Overview
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.10.6 Key Strategies
11.11 Siemens (Siemens Healthineers)
11.11.1 Company Overview
11.11.2 Product Overview
11.11.3 Financial Overview
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.11.6 Key Strategies11.12 Sandoz International GmbH
11.12.1 Company Overview
11.12.2 Product Overview
11.12.3 Financial Overview
11.12.4 Key Developments
11.12.5 SWOT Analysis
11.12.6 Key Strategies
11.13 Others
Chapter 12 Appendix
LIST OF TABLES
TABLE 1. HEPATITIS TEST SOLUTION DIAGNOSIS MARKET SYNOPSIS, 2023-2030
TABLE 2. HEPATITIS TEST SOLUTION DIAGNOSIS MARKET ESTIMATES AND FORECAST, 2023-2030 (USD Billion)
TABLE 3. GLOBAL HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2023-2030 (USD Billion)
TABLE 4. GLOBAL HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2023-2030 (USD Billion)
TABLE 5. GLOBAL HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2023-2030 (USD Billion)
TABLE 6. NORTH AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2023-2030 (USD Billion)
TABLE 7. NORTH AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2023-2030 (USD Billion)
TABLE 8. NORTH AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2023-2030 (USD Billion)
TABLE 9. US: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2023-2030 (USD Billion)
TABLE 10. US: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2023-2030 (USD Billion)
TABLE 11. US: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2023-2030 (USD Billion)
TABLE 12. CANADA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2023-2030 (USD Billion)
TABLE 13. CANADA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2023-2030 (USD Billion)
TABLE 14. CANADA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2023-2030 (USD Billion)
TABLE 15. LATIN AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2023-2030 (USD Billion)
TABLE 16. LATIN AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2023-2030 (USD Billion)
TABLE 17. LATIN AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2023-2030 (USD Billion)
TABLE 18. EUROPE: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2023-2030 (USD Billion)
TABLE 19. EUROPE: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2023-2030 (USD Billion)
TABLE 20. EUROPE: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2023-2030 (USD Billion)
TABLE 21. WESTERN EUROPE: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2023-2030 (USD Billion)
TABLE 22. WESTERN AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2023-2030 (USD Billion)
TABLE 23. WESTERN EUROPE: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2023-2030 (USD Billion)
TABLE 24. EASTERN EUROPE: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2023-2030 (USD Billion)
TABLE 25. WESTERN AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2023-2030 (USD Billion)
TABLE 26. EASTERN EUROPE: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2023-2030 (USD Billion)
TABLE 27. ASIA-PACIFIC: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2023-2030 (USD Billion)
TABLE 28. ASIA-PACIFIC: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2023-2030 (USD Billion)
TABLE 29. ASIA-PACIFIC: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2023-2030 (USD Billion)
TABLE 30. MIDDLE EAST & AFRICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2023-2030 (USD Billion)
TABLE 31. MIDDLE EAST & AFRICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2023-2030 (USD Billion)
TABLE 32. MIDDLE EAST & AFRICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2023-2030 (USD Billion)
LIST OF FIGURES
FIGURE 1. RESEARCH PROCESS
FIGURE 2. SEGMENTATION OF THE GLOBAL HEPATITIS TEST SOLUTION DIAGNOSIS MARKET
FIGURE 3. MARKET DYNAMICS OF THE GLOBAL HEPATITIS TEST SOLUTION DIAGNOSIS MARKET
FIGURE 4. HEPATITIS TEST SOLUTION DIAGNOSIS MARKET SHARE, BY TYPE, 2023
FIGURE 5. HEPATITIS TEST SOLUTION DIAGNOSIS MARKET SHARE, BY END USER, 2023
FIGURE 6. HEPATITIS TEST SOLUTION DIAGNOSIS MARKET SHARE, BY REGION, 2023
FIGURE 7. NORTH AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET SHARE, BY COUNTRY, 2023
FIGURE 8. EUROPE: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET SHARE, BY COUNTRY, 2023
FIGURE 9. ASIA-PACIFIC: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET SHARE, BY COUNTRY, 2023
FIGURE 10. MIDDLE EAST & AFRICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET SHARE, BY REGION, 2023
FIGURE 11. HEPATITIS TEST SOLUTION DIAGNOSIS MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 12. ABBOTT: KEY FINANCIALS
FIGURE 13. ABBOTT: SEGMENTAL REVENUE
FIGURE 14. ABBOTT: REGIONAL REVENUE
FIGURE 15. BIOMÉRIEUX SA: KEY FINANCIALS
FIGURE 16. BIOMÉRIEUX SA: SEGMENTAL REVENUE
FIGURE 17. BIOMÉRIEUX SA.: REGIONAL REVENUE
FIGURE 18. BIO-RAD LABORATORIES, INC.: KEY FINANCIALS
FIGURE 19. BIO-RAD LABORATORIES, INC.: SEGMENTAL REVENUE
FIGURE 20. BIO-RAD LABORATORIES, INC: REGIONAL REVENUE
FIGURE 21. DANAHER: KEY FINANCIALS
FIGURE 22. DANAHER: SEGMENTAL REVENUE
FIGURE 23. DANAHER: REGIONAL REVENUE
FIGURE 24. DIASORIN S.P.A: KEY FINANCIALS
FIGURE 25. DIASORIN S.P.A: SEGMENTAL REVENUE
FIGURE 26. DIASORIN S.P.A: REGIONAL REVENUE
FIGURE 27. MIRACA HOLDINGS INC. (FUJIREBIO, INC.): KEY FINANCIALS
FIGURE 28. MIRACA HOLDINGS INC. (FUJIREBIO, INC.): SEGMENTAL REVENUE
FIGURE 29. MIRACA HOLDINGS INC. (FUJIREBIO, INC.): REGIONAL REVENUE
FIGURE 30. GRIFOLS: KEY FINANCIALS
FIGURE 31. GRIFOLS: SEGMENTAL REVENUE
FIGURE 32. GRIFOLS: REGIONAL REVENUE
FIGURE 33. ONSITE LAB HOLDING AG (MEDMIRA, INC.): KEY FINANCIALS
FIGURE 34. ONSITE LAB HOLDING AG (MEDMIRA, INC.): SEGMENTAL REVENUE
FIGURE 35. ONSITE LAB HOLDING AG (MEDMIRA, INC.): REGIONAL REVENUE
FIGURE 36. QIAGEN: KEY FINANCIALS
FIGURE 37. QIAGEN: SEGMENTAL REVENUE
FIGURE 38. QIAGEN: REGIONAL REVENUE
FIGURE 39. ROCHE HOLDING AG (ROCHE DIAGNOSTICS): KEY FINANCIALS
FIGURE 40. ROCHE HOLDING AG (ROCHE DIAGNOSTICS): SEGMENTAL REVENUE
FIGURE 41. ROCHE HOLDING AG (ROCHE DIAGNOSTICS): REGIONAL REVENUE
FIGURE 42. SIEMENS (SIEMENS HEALTHINEERS): KEY FINANCIALS
FIGURE 43. SIEMENS (SIEMENS HEALTHINEERS): SEGMENTAL REVENUE
FIGURE 44. SIEMENS (SIEMENS HEALTHINEERS): REGIONAL REVENUE
FIGURE 45. SANDOZ INTERNATIONAL GMBH: KEY FINANCIALS
FIGURE 46. SANDOZ INTERNATIONAL GMBH: SEGMENTAL REVENUE
FIGURE 47. SANDOZ INTERNATIONAL GMBH: REGIONAL REVENUE
